A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Lymphocytic Leukemia
• Intervention / Treatment: Drug: Acalabrutinib (ACP-196); Drug: Rituximab; Drug: Idelalisib; Drug: Bendamustine

• Study Type: Interventional
• Enrollment (Actual): 310
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia, 5000
    • Research Site
  • Box Hill, Australia, 3128
    • Research Site
  • Frankston, Australia, 3199
    • Research Site
  • Geelong, Australia, 3220
    • Research Site
  • Gosford, Australia, 2250
    • Research Site
  • Hobart, Australia, 7000
    • Research Site
  • Kogarah, Australia, 2217
    • Research Site
  • Murdoch, Australia, 6150
    • Research Site
  • Nedlands, Australia, 6009
    • Research Site
  • South Brisbane, Australia, 4101
    • Research Site
  • Woodville, Australia, 5011
    • Research Site
• Austria
  • Linz, Austria, 4010
    • Research Site
  • Salzburg, Austria, 5020
    • Research Site
  • Wels, Austria, 4600
    • Research Site
  • Wien, Austria, 1130
    • Research Site
  • Wien, Austria, 1160
    • Research Site
• Belgium
  • Antwerpen, Belgium, 2060
    • Research Site
  • Ghent, Belgium, 9000
    • Research Site
  • Roeselare, Belgium, 8900
    • Research Site
  • Yvoir, Belgium, 5530
    • Research Site
• Bulgaria
  • Pleven, Bulgaria, 5800
    • Research Site
  • Plovdiv, Bulgaria, 4002
    • Research Site
  • Stara Zagora, Bulgaria, 6000
    • Research Site
  • Vratsa, Bulgaria, 3000
    • Research Site
• Canada
  • Calgary, Canada, T2N 2T9
    • Research Site
  • Montreal, Canada, H3T 1E2
    • Research Site
  • Ottawa, Canada, K1H 8L6
    • Research Site
  • Regina, Canada, S4T 7T1
    • Research Site
  • Saint John, Canada, E2L 4L2
    • Research Site
  • Toronto, Canada, M5G 2M9
    • Research Site
  • Toronto, Canada, M4N 3M5
    • Research Site
  • Ontario
    • Barrie, Ontario, Canada, L4M 6M2
      • Research Site
• Croatia
  • Zadar, Croatia, 23 000
    • Research Site
  • Zagreb, Croatia, 10 000
    • Research Site
• Czechia
  • Brno, Czechia, 625 00
    • Research Site
  • Novy Hradec Kralove, Czechia, 500 05
    • Research Site
  • Olomouc, Czechia, 779 00
    • Research Site
  • Ostrava Poruba, Czechia, 708 52
    • Research Site
  • Plzen - Lochotin, Czechia, 304 60
    • Research Site
  • Praha 10, Czechia, 100 34
    • Research Site
• France
  • Bordeaux, France, 33076, FR
    • Research Site
  • Brest, France, 29609
    • Research Site
  • Montpellier, France, 34295
    • Research Site
  • Nantes cedex 1, France, 44093
    • Research Site
  • Paris, France, 75010
    • Research Site
  • Paris cedex 13, France, 75651
    • Research Site
  • Perpignan, France, 66000
    • Research Site
  • Provence Alpes Cote D'Azur, France, 13273
    • Research Site
  • Rennes Cedex, France, 35000
    • Research Site
  • Rouen, France, 76038
    • Research Site
• Germany
  • Aschaffenburg, Germany, 63739
    • Research Site
  • Dresden, Germany, 1307
    • Research Site
  • Munchen, Germany, 81377
    • Research Site
  • Mutlangen, Germany, 73557
    • Research Site
  • Ulm, Germany, 89081
    • Research Site
• Hong Kong
  • HongKong, Hong Kong, 150001
    • Research Site
  • Pok Fu Lam, Hong Kong
    • Research Site
• Hungary
  • Budapest, Hungary, 1122
    • Research Site
  • Debrecen, Hungary, 4032
    • Research Site
  • Gyula, Hungary, 5700
    • Research Site
  • Kaposvár, Hungary, 7400
    • Research Site
• Israel
  • Ashkelon, Israel, 7830604
    • Research Site
  • Haifa, Israel, 34362
    • Research Site
  • Jerusalem, Israel, 9112001
    • Research Site
  • Kfar Saba, Israel, 4428164
    • Research Site
  • Nahariya, Israel, 22100
    • Research Site
  • Petah Tikvah, Israel, 49102
    • Research Site
• Italy
  • Aviano, Italy, 33081
    • Research Site
  • Bergamo, Italy, 24127
    • Research Site
  • Brescia, Italy, 25123
    • Research Site
  • Firenze, Italy, 50134
    • Research Site
  • Genova, Italy, 16132
    • Research Site
  • Genova, Italy, 16126
    • Research Site
  • Meldola, Italy, 47014
    • Research Site
  • Milan, Italy, 20162
    • Research Site
  • Milano, Italy, 20132
    • Research Site
  • Modena, Italy, 41100
    • Research Site
• Korea, Republic of
  • Busan, Korea, Republic of, 49241
    • Research Site
  • Daegu, Korea, Republic of, 41944
    • Research Site
  • Dong-gu, Korea, Republic of, 44033
    • Research Site
  • Gyeonggi-do, Korea, Republic of, 13620
    • Research Site
  • Incheon, Korea, Republic of, UNK
    • Research Site
  • Jeonju-si, Korea, Republic of, 54907
    • Research Site
  • Seoul, Korea, Republic of, 3080
    • Research Site
  • Seoul, Korea, Republic of, 3722
    • Research Site
• New Zealand
  • Addington, New Zealand, 8011
    • Research Site
  • Dunedin, New Zealand, 9016
    • Research Site
  • Palmerston North, New Zealand, 4442
    • Research Site
  • Tauranga, New Zealand, 3112
    • Research Site
• Poland
  • Bialystok, Poland, 15-276
    • Research Site
  • Bydgoszcz, Poland, 85-168
    • Research Site
  • Gdansk, Poland, 80-129
    • Research Site
  • Kraków, Poland, 30-727
    • Research Site
  • Lodz, Poland, 93-510
    • Research Site
  • Lublin, Poland, 20-081
    • Research Site
  • Woj. Podkarpackie, Poland, 36-200
    • Research Site
• Russian Federation
  • Novosibirsk, Russian Federation, 630087
    • Research Site
  • Obninsk, Russian Federation, 249031
    • Research Site
  • Penza, Russian Federation, 440008
    • Research Site
  • Ryazan, Russian Federation, 390000
    • Research Site
  • Sochi, Russian Federation, Unk
    • Research Site
  • St. Petersburg, Russian Federation, 197341
    • Research Site
  • St. Petersburg, Russian Federation, 194044
    • Research Site
  • Tula, Russian Federation, 300053
    • Research Site
  • Volgograd, Russian Federation, Unk
    • Research Site
  • Yaroslavl, Russian Federation, 150023
    • Research Site
  • Yekaterinburg, Russian Federation, 620072
    • Research Site
• Singapore
  • SGP, Singapore, 169608
    • Research Site
  • SGP, Singapore, 188770
    • Research Site
  • SGP, Singapore, 217562
    • Research Site
• Slovakia
  • Bratislava, Slovakia, 833 10
    • Research Site
  • Kosice, Slovakia, 040 01
    • Research Site
• Spain
  • Badalona, Spain, 8916
    • Research Site
  • Madrid, Spain, 28031
    • Research Site
  • Madrid, Spain, 28041
    • Research Site
  • Madrid, Spain, 28009
    • Research Site
  • Madrid, Spain, 28006
    • Research Site
  • Madrid, Spain, 28033
    • Research Site
  • Majadahonda, Spain, 28222
    • Research Site
  • Salamanca, Spain, 37007
    • Research Site
  • Santander, Spain, 39008
    • Research Site
  • Valencia, Spain, 46026
    • Research Site
• Sweden
  • Goeteborg, Sweden, 413 46
    • Research Site
  • Lulea, Sweden, 97180
    • Research Site
  • Stockholm, Sweden, 171 76
    • Research Site
• Taiwan
  • Hualien, Taiwan, 970
    • Research Site
  • Tainan, Taiwan, 70403
    • Research Site
  • Taipei, Taiwan, 100
    • Research Site
• Ukraine
  • Cherkasy, Ukraine, 18009
    • Research Site
  • Dnipropetrovsk, Ukraine, 49102
    • Research Site
  • Ivano-Frankivsk, Ukraine
    • Research Site
  • Khmelnytsky, Ukraine, 29000
    • Research Site
  • Kyiv, Ukraine
    • Research Site
  • Kyiv, Ukraine, 03022
    • Research Site
  • Zhytomir, Ukraine, 10002
    • Research Site
• United Kingdom
  • Birmingham, United Kingdom, B9 5SS
    • Research Site
  • Cambridge, United Kingdom, CB2 0QQ
    • Research Site
  • Canterbury, United Kingdom, CT1 3NG
    • Research Site
  • Leicester, United Kingdom, LE1 7RH
    • Research Site
  • London, United Kingdom, SE5 9RS
    • Research Site
  • Maidstone, United Kingdom, ME16 9QQ
    • Research Site
  • Manchester, United Kingdom, M20 4BX
    • Research Site
  • Southampton, United Kingdom, SO16 6YD
    • Research Site
  • Wolverhampton, United Kingdom, WV10 0QP
    • Research Site
• United States
  • Arizona
    • Chandler, Arizona, United States, 85224
      • Research Site
  • California
    • Oxnard, California, United States, 93030
      • Research Site
  • Georgia
    • Athens, Georgia, United States, 30607
      • Research Site
  • Illinois
    • Joliet, Illinois, United States, 60435
      • Research Site
  • Iowa
    • Cedar Rapids, Iowa, United States, 52403
      • Research Site
  • Kentucky
    • Mount Sterling, Kentucky, United States, 40353
      • Research Site
  • Minnesota
    • Saint Cloud, Minnesota, United States, 56303
      • Research Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68506
      • Research Site
  • New Jersey
    • Brick, New Jersey, United States, 08724
      • Research Site
  • New York
    • Nyack, New York, United States, 10960
      • Research Site
  • Ohio
    • Canton, Ohio, United States, 44719
      • Research Site
  • Texas
    • Fort Sam Houston, Texas, United States, 78234
      • Research Site
    • Round Rock, Texas, United States, 78665
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Men and women ≥ 18 years of age.
2. ECOG performance status of 0 to 2.

3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):

   1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B-cell marker (CD19, CD20, or CD23) and CD5.
   2. Prolymphocytes may comprise ≤ 55% of blood lymphocytes.
   3. Presence of ≥ 5 x 10^9 B lymphocytes/L (5000/μL) in the peripheral blood (at any point since initial diagnosis).
4. Must have documented CD20-positive CLL.

5. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:

   1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/μL).
   2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
   3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
   4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a LDT of < 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of < 30 x 10^9/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
   5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
   6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:

   i. Unintentional weight loss ≥ 10% within the previous 6 months before screening.

   ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities).

   iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before screening without evidence of infection.

   iv. Night sweats for > 1 month before screening without evidence of infection.

6. Meet the following laboratory parameters:

   1. ANC ≥ 750 cells/μL (0.75 x 10^9/L), or ≥ 500 cells/μL (0.50 x 10^9/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
   2. Platelet count ≥ 50,000 cells/μL (50 x 10^9/L), or ≥ 30,000 cells/μL (30 x 10^9/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded. If an Investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75,000 cells/μL (75 x 10^9/L).
   3. Serum AST and ALT ≤ 2.0 x ULN.
   4. Total bilirubin ≤ 1.5 x ULN.
   5. Estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female].
7. Must have received ≥ 1 prior systemic therapies for CLL. Note: Single-agent steroids or localized radiation are not considered a prior line of therapy. If a single-agent anti-CD20 antibody was previously administered, subjects must have received ≥ 2 doses.
8. Women who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
11. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules without difficulty.
12. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion Criteria:

1. Known CNS lymphoma or leukemia.
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
3. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (> 20 mg daily of prednisone or equivalent).
4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor (e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if Investigator's choice for treatment in Arm B is idelalisib with rituximab. Bendamustine retreatment is allowed if the prior response to bendamustine lasted > 24 months.
5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
6. Corticosteroid use > 20 mg daily prednisone equivalent within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded.
7. Prior radio- or toxin-conjugated antibody therapy.
8. Prior allogeneic stem cell transplant or prior autologous transplant within 6 months of first dose of study drug(s) or presence of graft-vs-host disease or receiving treatment for graft-vs-host disease.
9. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.

10. History of prior malignancy except for the following:

    1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer.
    3. Adequately treated carcinoma in situ without current evidence of disease.
11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc > 480 msec (calculated using Fridericia's formula: QT/RR^0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
13. Received a live virus vaccination within 28 days of first dose of study drug.
14. Known history of infection with HIV or any uncontrolled active systemic infection (e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if positive, reactivity against the HIV-specific p24 antigen).
15. Active CMV infection (active viremia as evidenced by positive polymerase chain reaction [PCR] result for CMV DNA).

16. Serologic status reflecting active hepatitis B or C infection.

    1. Subjects who are anti-HBc positive and who are surface antigen negative will need to have a negative PCR result before randomization. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
    2. Subjects who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.
17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
18. History of or ongoing drug-induced pneumonitis.
19. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis.
20. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease).
22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
24. Requires treatment with a strong CYP3A inhibitor/inducer.
25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
26. Breast feeding or pregnant.
27. Concurrent participation in another therapeutic clinical trial.
28. Prothrombin time/INR or aPTT (in the absence of a Lupus anticoagulant) > 2.0 x ULN. Exception: Subjects receiving warfarin are excluded, however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the medical monitor.
29. History of confirmed progressive multifocal leukoencephalopathy (PML)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Acalabrutinib (ACP-196); Acalabrutinib (ACP-196) Monotherapy	Drug: Acalabrutinib (ACP-196); Acalabrutinib monotherapy
Active Comparator: Rituximab Plus Idelalisib or Bendamustine; Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine	Drug: Rituximab; Rituximab in combination with idelalisib or bendamustine; Drug: Idelalisib; Idelalisib in combination with rituximab; Drug: Bendamustine; Bendamustine in combination with rituximab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment	To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.	IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) Per Investigator Assessment	PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.	From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis	IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)	IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021	IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)	Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Overall Survival (OS)	Overall Survival (OS) was based on data cutoff date of 03Sep2021	From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.	Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.	IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff	Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.	Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff	Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.	From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.

Collaborators and Investigators

• Sponsor: Acerta Pharma BV
• Investigators: Study Director: Acerta Clinical Trials, 1-888-292-9613; acertamc@dlss.com

Publications and helpful links

General Publications

• Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1.
• Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.

Helpful Links

• Redacted CSP
• Redacted SAP
• Redacted CSR synopsis

Study record dates

Study Major Dates

• Study Start (Actual): February 2, 2017
• Primary Completion (Actual): September 3, 2021
• Study Completion (Estimated): September 3, 2027

Study Registration Dates

• First Submitted: November 18, 2016
• First Submitted That Met QC Criteria: November 18, 2016
• First Posted (Estimated): November 22, 2016

Study Record Updates

• Last Update Posted (Actual): March 18, 2024
• Last Update Submitted That Met QC Criteria: March 15, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: CLL; BTK; Bruton Tyrosine Kinase; acalabrutinib; ACP-196
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Hematologic Diseases; Leukemia, B-Cell; Chronic Disease; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Bendamustine Hydrochloride; Rituximab; Acalabrutinib; Idelalisib
• Other Study ID Numbers: ACE-CL-309; 2015-004454-17 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No